Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer

Oncogenesis

Volumn 3, Issue , 2014, Pages

  Lattanzio, R ^a,b,c   Ghasemi, R ^a,b,d   Brancati, F ^a   Sorda, R L ^a,b,c   Tinari, N ^a,b,c   Perracchio, L ^e   Iacobelli, S ^a,b,c   Mottolese, M ^e   Natali, P G ^a   Piantelli, M ^a,b,c  

^a UNIVERSITY OF CHIETI   (Italy)

^b Center of Excellence on Aging   (Italy)

^c MediaPharma srl   (Italy)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NECTIN 4; PROTEIN; UNCLASSIFIED DRUG; GLYCOPROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CELL MEMBRANE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT RELAPSE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY;

EID: 84907357920     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.32     Document Type: Article

References (32)

1. Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003; 39: 1718-1729.
2. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004; 9: 606-616.
3. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000; 355: 1822.
4. Tyczynski JE, Bray F, Parkin DM. Breast cancer in Europe. ENCR Cancer Fact Sheets 2002; 2: 1-4.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
6. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93: 979-989.
7. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
8. Takai Y, Miyoshi J, Ikeda W, Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol 2008; 9: 603-615.
9. Takahashi K, Nakanishi H, Miyahara M, Mandai K, Satoh K, Satoh A et al. Nectin/PRR: an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein. J Cell Biol 1999; 145: 539-549.
10. Sakisaka T, Ikeda W, Ogita H, Fujita N, Takai Y. The roles of nectins in cell adhesions: cooperation with other cell adhesion molecules and growth factor receptors. Curr Opin Cell Biol 2007; 19: 593-602.
11. Fabre S, Reymond N, Cocchi F, Menotti L, Dubreuil P, Campadelli-Fiume G et al. Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C'-C"-D beta-strands of the nectin1 V domain. J Biol Chem 2002; 277: 27006-27013.
12. Reymond N, Fabre S, Lecocq E, Adelaide J, Dubreuil P, Lopez M. Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. J Biol Chem 2001; 276: 43205-43215.
13. Athanassiadou AM, Patsouris E, Tsipis A, Gonidi M, Athanassiadou P. The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma. Folia Histochem Cytobiol 2011; 49: 26-33.
14. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M et al. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 2010; 134: 835-845.
15. Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, Lopez M. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem 2005; 280: 19543-19550.
16. Fabre-Lafay S, Monville F, Garrido-Urbani S, Berruyer-Pouyet C, Ginestier C, Reymond N et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 2007; 7: 73.
17. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009; 69: 6694-6703.
18. Brancati F, Fortugno P, Bottillo I, Lopez M, Josselin E, Boudghene-Stambouli O et al. Mutations in PVRL4, encoding cell adhesion molecule nectin-4, cause ectodermal dysplasia-syndactyly syndrome. Am J Hum Genet 2010; 87: 265-273.
19. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama 2006; 295: 2492-2502.
20. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
21. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
22. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
23. Viale G. Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment. Breast 2009; 18(Suppl 3): S32-S36.
24. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011 22: 1736-1747.
25. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VH et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011; 480: 530-533.
26. Noyce RS, Richardson CD. Nectin 4 is the epithelial cell receptor for measles virus. Trends Microbiol 2012; 20: 429-439.
27. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006; 25: 2273-2284.
28. Astellas Pharma Inc. A Phase 1 Study of the safety and pharmacokinetics of escalating doses of AGS-22M6E or ASG-22CE given as monotherapy followed by expansion cohorts in subjects with malignant solid tumors that express nectin-4. Current Controlled Trials 2013; http://clinicaltrials.gov/ct2/show/NCT01409135/ .
29. Querzoli P, Pedriali M, Rinaldi R, Lombardi AR, Biganzoli E, Boracchi P et al. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res 2006; 12: 6696-6701.
30. Lattanzio R, Marchisio M, La Sorda R, Tinari N, Falasca M, Alberti S et al. Overexpression of activated phospholipase Cgamma1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy. Int J Cancer 2013; 132: 1022-1031.
31. Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R et al. A divergent role for estrogen receptor-beta in node-positive and nodenegative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 2008; 10: R74.
32. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.